Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LO MILI.
TRI LO SPRINTEC vs TRI-LO-MILI
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancyAcne vulgaris (in females at least 15 years old who have no known contraindications and have achieved menarche)
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation; undergoes glucuronidation and sulfation. Norgestimate: rapidly hydrolyzed to norelgestromin and levonorgestrel; norelgestromin further metabolized to levonorgestrel; both undergo hydroxylation and conjugation, primarily by CYP3A4.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Norgestimate: 99% bound to albumin and SHBG; ethinyl estradiol: 97% bound to albumin.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Norgestimate: approximately 2.5 L/kg; ethinyl estradiol: approximately 1.5 L/kg; indicates moderate tissue distribution.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: norgestimate ~90%; ethinyl estradiol ~40% (due to first-pass metabolism).
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No dosage adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 mL/min) or acute renal failure.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in acute or chronic hepatic disease, including Child-Pugh Class A, B, or C. No dose adjustment possible.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Not indicated for use before menarche. For post-menarchal adolescents: same as adult dosing.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for use in postmenopausal women. No specific geriatric dosage adjustment defined due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
Thrombotic and cardiovascular events (e.g., stroke, MI, thromboembolism), hepatic disease (including liver tumors), hypertension, gallbladder disease, carbohydrate/lipid metabolic effects, headache, irregular bleeding, depression, fluid retention, hereditary angioedema, chloasma, retinal thrombosis, use in pregnancy and postpartum.
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
Current or past thrombosis (e.g., DVT, PE), cerebrovascular or coronary artery disease, known thrombophilia, history of myocardial infarction or stroke, uncontrolled hypertension, diabetes with vascular involvement, headache with focal neurological symptoms (e.g., migraine with aura if age >35), major surgery with prolonged immobilization, known or suspected pregnancy, breastfeeding, liver disease (including tumors), undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia, age >35 and smoking ≥15 cigarettes/day, hypersensitivity to any component.
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid large quantities. May be taken with or without food. Maintain consistent dietary intake of folate-rich foods; some oral contraceptives may affect folate metabolism.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
Pregnancy Category X. Use is contraindicated in pregnancy. Tri-Lo-Mili (norgestimate/ethinyl estradiol) is associated with increased risk of fetal harm, including cardiovascular defects and limb reduction defects, when taken inadvertently during early pregnancy. First trimester exposure carries highest risk; second and third trimester use associated with potential for other adverse outcomes, including neonatal withdrawal.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Excreted in human milk; may reduce milk production and affect infant. M/P ratio not established. Use in breastfeeding is not recommended, especially in early postpartum period due to potential estrogenic effects on infant and milk supply.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
No dosing adjustments exist as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) would theoretically require dose increase if used, but use is not recommended. No clinical data to guide adjustments.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Lo-Mili (norgestimate/ethinyl estradiol) is a triphasic oral contraceptive with varying hormone levels across three phases. Prescribe with a fixed dosing schedule; missed pills increase breakthrough bleeding risk. Be aware of increased venous thromboembolism risk, especially in smokers over 35. May reduce efficacy with enzyme-inducing drugs. Monitor for hypertension, hyperkalemia (due to drospirenone component if applicable - note: Tri-Lo-Mili contains norgestimate, not drospirenone). Consider alternative if patient has migraine with aura.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one tablet daily at the same time each day.If you miss a pill, follow the package instructions or consult your healthcare provider.Use a backup contraceptive method (e.g., condoms) for the first 7 days of starting Tri-Lo-Mili.Report signs of blood clots (leg pain, chest pain, sudden shortness of breath) or stroke (sudden severe headache, vision changes).Do not smoke while taking this medication, especially if over 35 years old.Inform your doctor about all medications, including antibiotics and herbal supplements (e.g., St. John's wort).